haematologica
Journal of the Ferrata Storti Foundation

Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma

by Jessie Zhao, Tiffany Khong, Malgorzata Gorniak, Abir Khaled, Zac McDonald, John Reynolds, Sridurga Mithraprabhu, Nicholas Bingham, Suehli Lim, Daniel Wong, Anna Johnston, Olga Motorna, Nicholas Murphy, Hang Quach, Liqiang Yang, and Andrew Spencer

Received: May 28, 2024.
Accepted: October 29, 2024.

Citation: Jessie Zhao, Tiffany Khong, Malgorzata Gorniak, Abir Khaled, Zac McDonald, John Reynolds, Sridurga Mithraprabhu, Nicholas Bingham, Suehli Lim, Daniel Wong, Anna Johnston, Olga Motorna, Nicholas Murphy, Hang Quach, Liqiang Yang, and Andrew Spencer. Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma. Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.285933 [Epub ahead of print]

Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma

Jessie Zhao[1,2], Tiffany Khong[1,2], Malgorzata Gorniak[3], Abir Khaled[4], Zac McDonald[4], John Reynolds[1,2], Sridurga Mithraprabhu[1,2], Nicholas Bingham[1,2], Suehli Lim[1,2], Daniel Wong[1,2], Anna Johnston[5], Olga Motorna[6], Nicholas Murphy[5], Hang Quach[7], Liqiang Yang[4], and Andrew Spencer[1,2]

[1]Department of Malignant Haematology & Stem Cell Transplantation, The Alfred Hospital, Melbourne, Australia
[2]Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
[3]Alfred Pathology, The Alfred Hospital, Melbourne, Australia
[4]Rapid Novor, Kitchener, Canada
[5]Department of Haematology, Royal Hobart Hospital, Hobart, Australia
[6]Department of Haematology, Eastern Health, Melbourne, Australia
[7]Department of Haematology, St. Vincent's Hospital Melbourne, Melbourne, Australia

Corresponding Author:
A. Spencer - andrew.spencer@monash.edu

Authors' Contributions:
AS designed the studies, performed research, analysed data, wrote the initial draft and final draft, supervised the project. JZ annotated data, analysed data, wrote the initial draft and final draft. TK, MG, AK, ZM, SM, NB, SL, DW, AJ, OM, NM, HQ, and LY performed research, approved the final draft. JR annotated data, analysed data, approved the final draft.

Authors' Disclosures:
AK: Rapid Novor Inc.: Current Employment. ZM: Rapid Novor Inc.: Current Employment. JR: Abbvie: Current equity holder in publicly-traded company, Research Funding; HemaLogix: Consultancy; Novartis AG: Current equity holder in publicly-traded company; Novartis Australia: Honoraria; Alcon AG: Current equity holder in publicly-traded company. OM: Antengene: Consultancy. HQ: Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: receipt of study materials, Research Funding; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: receipt of study materials, Leadership or fiduciary role, Research Funding; Sanofi: Consultancy, Other: receipt of study materials; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Leadership or fiduciary role. LY: Rapid Novor Inc.: Current Employment, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees. AS: Antengene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Haemalogix: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Honoraria, Research Funding, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding,

Speakers Bureau; IDP Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.

Running Title:
Comparison of EasyM and EuroFlow MRD in MM

Data Sharing Statement:
Data available on reasonable request to the corresponding author.

Word Count:
1499 words.
1 table and 2 figures.
1 supplementary file (2 supplementary figures).

Trial Registration:
Australasian Leukaemia and Lymphoma Group MM19 ANZCTR.org.au identifier: ACTRN12616000772448.
Australasian Leukaemia and Lymphoma Group MM21 ANZCTR.org.au identifier: ACTRN12618001490268.

Minimal residual disease (MRD) negativity is increasingly recognised as the optimal measure of therapeutic response in multiple myeloma (MM) and is associated with improved progression free and overall survival.[1] Bone marrow (BM) MRD assessment with next-generation sequencing (NGS) or next-generation flow cytometry (NGF) can achieve a minimum sensitivity of 10^{-5},[2] however requires an invasive procedure. Additionally, this single-site BM biopsy may be limited by specimen quality and failure to capture MM's spatial heterogeneity.[3] Peripheral blood-based mass spectrometry (PB-based MS) can sequentially quantify unique amino acid sequences and unique molecular masses of monoclonal proteins (M-proteins),[4] offering the potential for highly sensitive, non-invasive sequential MRD assessment. Two MS methods, the clonotypic peptide and intact immunoglobulin light chain approaches, have been employed.[5] The clonotypic peptide approach has lower throughput but is personalised and highly sensitive, able to detect residual M-proteins at a level of 0.001g/L.[6]

In this context, we retrospectively evaluated the PB clonotypic MS EasyM assay in MM patients undergoing sequential EuroFlow NGF MRD. MM patients enrolled in the Australasian Leukaemia and Lymphoma Group MM19 (ANZCTR.org.au identifier: ACTRN12616000772448) and MM21 (ANZCTR.org.au identifier: ACTRN12618001490268) trials with measurable M-protein ≥2g/L by serum protein electrophoresis and/or free light chains (FLC) ≥100mg/L at baseline were identified. Briefly, the MM19 trial evaluated the addition of ixazomib (ITd) to thalidomide and dexamethasone (Td) consolidation for 12 months in transplant-eligible newly diagnosed MM patients undergoing front-line autologous stem cell transplantation (ASCT), whilst the MM21 trial evaluated an intensive salvage approach using daratumumab-lenalidomide-dexamethasone (DRd) as re-induction (DRd x 4) and post-ASCT consolidation (DRd x 12 followed by R maintenance until progression) in transplant-eligible MM patients failing (<partial response as best response) front-line bortezomib-based induction therapy.[7] EuroFlow NGF MRD status was determined from BM samples at pre-ASCT, post-ASCT, and end of consolidation timepoints in MM19 and MM21 and additionally post-cycle 2 of consolidation in MM21 (Supplementary Figure 1). Matched serum samples and additionally unmatched samples post-cycle 7 of consolidation in MM19 were evaluated with EasyM. Protocols were approved by ethics committees of all participating centres.

Utilising the standardised 8-colour EuroFlow platform,[8] samples were analysed with a Navios flow cytometer (Beckman Coulter, USA) and Infinicyt software (Cytognos SL, Spain). Test sensitivity at a level of 10^{-5} was defined with thresholds for the limit of detection (LOD) of 20 cells in $2x10^6$ nucleated BM cells and the lower limit of quantification (LLOQ) of 50 cells in $5x10^6$ nucleated BM cells according to International Clinical Cytometry Society consensus guidelines.[9] Disease responses were assigned according to the International Myeloma Working Group consensus response criteria.[2]

EasyM, a commercial PB clonotypic MS assay (Rapid Novor, Canada), involves *de novo* amino acid sequencing of the full-length M-protein and quantification of unique peptides with parallel reaction monitoring.[10] After M-protein enrichment from the pre-ASCT serum sample and multienzymatic digestion, samples were analysed with liquid chromatography with tandem mass spectrometry (Supplementary Figure 2). The full length M-protein sequence was assembled with the proprietary REmAb antibody sequencing platform. Unique tryptic peptides were identified after alignment to germline sequences and the LLOQ and LOD were ascertained for two to three peptides for individual patients. The diagnostic sample underwent serial dilution in the control serum, trypsin digestion, and analysis with parallel

reaction monitoring assays. The LLOQ was the highest dilution at which the observed amount deviated from the expected amount by <20% and the coefficient of variation of duplicate injections was <20%. The clonotypic peptide with the lowest LLOQ was selected for tracking. To monitor an individual patient's M-protein, follow-up serum samples underwent digestion with trypsin and analysis with patient-specific parallel reaction monitoring assays to quantify the percent residual M-protein. Concordance between NGF and MS was assessed by the Chi-squared and McNemar's tests.

A total of 62 patients were identified for analysis. MS analysis was successful in 57 (92%) patients. The 5 remaining patients all had light chain MM with involved FLC of 182-5544mg/L; 4 were sequenced but unique peptides could not be identified and 1 could not be sequenced due to polyclonal background and low protein level. In regard to the immunoglobulin isotype, 79% of patients had IgG, 9% IgA, and 12% light chain MM. M-protein negativity by EasyM (MS-) was achieved in only 3 (5%) patients, all of whom were enrolled on MM21. MS- was first achieved at the pre-ASCT (light chain isotype), post-ASCT (IgG M-protein), and post-cycle 2 of consolidation (IgA M-protein) timepoints, respectively. All 3 patients remain in CR at 46-50 months post-ASCT. Sequential MS samples (Figure 1) revealed rising EasyM levels in 6 patients, coinciding with relapse in 2 patients and preceding relapse in 4 patients by 3, 15, 25, and 38 months. Matched BM NGF results were available for 5 patients at time of rising EasyM levels, and of note, 1 patient was NGF MRD negative (NGF-) whilst 4 patients were NGF MRD positive (NGF+).

A total of 136 serum samples for MS with matched BM for NGF were available, with 25 pre-ASCT, 47 post-ASCT, 27 post-cycle 2 of consolidation, and 37 end of consolidation samples (Table 1). Forty-five samples (33%) were NGF- compared to 7 (5%) MS- samples from 3 patients. MS- was 4%, 4%, 7%, and 5% at the 4 timepoints. NGF- was 8%, 23%, 37%, and 59% at the same timepoints. Ninety-eight (72%) samples were concordant. As patients progressed through treatment, the discordances between detectable M-protein by MS analysis and NGF- (MS+/NGF-) increased, accounting for 4%, 19%, 30%, and 54% of samples at the 4 timepoints (Figure 2). McNemar's test p-values were >0.999, 0.004, 0.008, and <0.001 for the 4 timepoints, indicating that MS+/NGF- were more likely than MS-/NGF+ discordances at all timepoints except for pre-ASCT. The Chi-squared test for association between MS and NGF was not significant at any of the 4 timepoints. Of the 32 matched samples with confirmed serological CR status, 9 (28%) were MS+/NGF+, 17 (53%) were MS+/NGF-, and 6 (19%) were MS-/NGF- (Chi-squared and McNemar's p-values of 0.149 and <0.001). In this small cohort, MS- was not significantly associated with progression free survival.

This study compared sequential PB-based EasyM MS and BM-based EuroFlow NGF MRD in transplant-eligible MM patients enrolled on 2 clinical trials. The overall concordance rate between EasyM MS and EuroFlow NGF was 72%. This is comparable to the concordance rate of 78% between clonotypic MS and BM-based NGS MRD in patients enrolled on the IFM 2009 trial,[11] supporting the high sensitivity and reproducibility of MS despite differences in patient population and therapy. Furthermore, we demonstrated that 53% of CR samples were MS+/NGF-, consistent with the improved sensitivity of EasyM over BM-based evaluation with 8-colour multiparameter flow cytometry (MPFC) with sensitivity of 10^{-4}, a mix of MPFC and NGF with sensitivity of 10^{-4} to 10^{-5}, and clonoSEQ NGS with sensitivity of 10^{-5} to 10^{-6}.[10,12-13] These data suggest MS could guide appropriate timing and rationalise BM-based MRD testing in patients achieving CR, although the optimal cut-off values and timing are unknown. The ultrasensitive nature of EasyM rendered few samples MS-. Studies have therefore calculated optimal MS- cut-offs and demonstrated EasyM MS+ predicts

progression free survival post-ASCT.[12-14] Prospective validation of clonotypic MS- cut-offs and clinical outcomes is required.

Rising M-protein levels by MS predicted progression, detecting relapse up to 38 months earlier than traditional electrophoretic methods. Consistent with this, doubling M-protein levels by EasyM over 6 months predicted relapse.[10] Furthermore, retrospective data from IFM 2009 demonstrated that progression was detected with MS 442 days earlier on average,[11] underscoring the argument for dynamic MS MRD monitoring. All discordant results were MS+/NGF-, with an increasing proportion as patients progressed through treatment, suggesting deepening responses and increased MS sensitivity. Although achieving BM MRD negativity is a strong prognostic factor, patients with MRD negativity at a sensitivity of 10^{-6} continue to relapse over time, highlighting the unmet need for more accurate MRD detection.[15] False negative NGF MRD results can be attributed to extramedullary disease, sampling error due to haemodilution, or the spatially heterogenous nature of bone marrow infiltration characteristic of MM, arguing for PB-based approaches for M-protein detection. Additionally, concordance between MS and NGF could be affected by the different half-lives of M-proteins, especially in the early stages of monitoring IgG M-proteins which have extended half-lives due to neonatal Fc receptor recycling. EasyM cut-offs for different M-protein isotypes at day +100 post-ASCT have been proposed but require further evaluation.[14]

In conclusion, the EasyM PB clonotypic MS assay appears to be more sensitive in detecting residual disease in MM than the validated and widely accepted BM EuroFlow NGF MRD approach with a sensitivity of 10^{-5}. Concordance between MS and NGF was poor, with 53% of CR samples showing detectable M-protein by EasyM MS despite EuroFlow NGF MRD negativity. Comparison of larger sample sets and validation through prospective clinical trials is warranted to better assess the clinical utility and implications of EasyM MRD positivity. However, this preliminary data highlights the potential of EasyM for highly sensitive, sequential PB-based clonotypic MS MRD monitoring in MM, and consequently complementing MRD assessment in extramedullary MM, facilitating early relapse detection and adaptive response-based therapy, and rationalising BM-based MRD assessments.

References

1. Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988-5999.
2. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.
3. Mithraprabhu S, Khong T, Ramachandran M, et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. Leukemia. 2017;31(8):1695-1705.
4. Barnidge DR, Dasari S, Botz CM, et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res. 2014;13(3):1419-1427.
5. Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021;11(2):24.
6. Bergen HR, 3rd, Dasari S, Dispenzieri A, et al. Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin Chem. 2016;62(1):243-251.
7. Lim S, Reynolds J, Quach H, et al. Preliminary analysis of the MM21 trial: response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients failing front-line bortezomib-based induction therapy. Blood. 2021;138(Supplement 1):1665.
8. Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094-2103.
9. Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31-39.
10. Liyasova M, McDonald Z, Taylor P, et al. A personalized mass spectrometry-based assay to monitor M-protein in patients with multiple myeloma (EasyM). Clin Cancer Res. 2021;27(18):5028-5037.
11. Noori S, Wijnands C, Langerhorst P, et al. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J. 2023;13(1):30.
12. Slade MJ, Khalid A, Fiala MA, et al. Clonotypic mass spectrometry with EasyM assay for detection of measurable residual disease in multiple myeloma. Blood. 2022;140(Supplement 1):4376-4377.
13. Fan H, Wang B, Qiu L, Ma B, An G. Monitoring minimal residual disease in patients with multiple myeloma by tracking serum M-protein using mass spectrometry. Blood. 2023;142(Supplement 1):1920.
14. Slade M, Khaled A, Fiala M, et al. Measurable residual disease status by clonotypic mass spectrometry with EasyM assay predicts outcomes following autologous hematopoietic cell transplant in multiple myeloma. Blood. 2023;142(Supplement 1):3354.
15. Fonseca R, Arribas M, Wiedmeier-Nutor JE, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023;13(1):32.

Table 1. **McNemar's Test of matched MS (EasyM) and NGF (EuroFlow platform) samples**. ASCT, autologous stem cell transplantation; CR, complete response; MS, mass spectrometry; NGF, next-generation flow cytometry.

	NGF+	**NGF-**	**McNemar's Test H0: equal discordances (+/- = -/+)**
All samples (n = 136)			
MS+	91	38	Statistic: 36.026
MS-	0	7	Exact probability: <0.001
Pre-ASCT (n = 25)			
MS+	23	1	Statistic: 0
MS-	0	1	Exact probability: >0.999
Post-ASCT (n = 47)			
MS+	36	9	Statistic: 7.111
MS-	0	2	Exact probability: 0.004
Post-cycle 2 of consolidation (n = 27)			
MS+	17	8	Statistic: 6.125
MS-	0	2	Exact probability: 0.008
End of consolidation (n = 37)			
MS+	15	20	Statistic: 18.050
MS-	0	2	Exact probability: <0.001
CR (n = 32)			
MS+	9	17	Statistic: 15.059
MS-	0	6	Exact probability: <0.001

Figure 1. **EasyM MRD kinetics in individual patients**. Patients with rising EasyM are highlighted in red. ASCT, autologous stem cell transplantation; M-protein, monoclonal protein.

Figure 2. **Matched MM MRD assessment by MS (EasyM) and NGF (EuroFlow platform)**. ASCT, autologous stem cell transplantation; EOT, end of therapy; MS, mass spectrometry; NGF, next-generation flow cytometry.


Percentage residual M-protein (log10)
100
10
1
0.1
0.01
Baseline
Pre-ASCT
Post-ASCT
Post-cycle 2 of consolidation
Post-cycle 7 of consolidation
End of consolidation


Percentage
100
90
80
70
60
50
40
30
20
10
0
92
4
0
4
77
19
0
4
63
30
0
7
41
54
0
5
Pre-ASCT
n=25
Post-ASCT
n=47
Mid-consolidation
n=27
EOT
n=37
MS+/NGF+
MS+/NGF-
MS-/NGF+
MS-/NGF-

Supplementary Figure 1. **MM19 and MM21 trial schema**. ASCT, autologous stem cell transplantation; DRd, daratumumab-lenalidomide-dexamethasone; ITd, ixazomib-thalidomide-dexamethasone; MM, multiple myeloma; MRD, minimal residual disease; MS, mass spectrometry; NGF, next-generation flow cytometry; PD, progressive disease; PR, partial response; R, lenalidomide; Td, thalidomide-dexamethasone.



Supplementary Figure 2. **Overview of the EasyM assay**. LC-MS/MS, liquid chromatography with tandem mass spectrometry; M-protein, monoclonal protein.